Latest Articles
Patient awarded Ksh157M payout for medical negligence - KBC Digital
Patient awarded Ksh157M payout for medical negligence KBC Digital
Published: June 4, 2025, 1:03 p.m.
Analysis of the influencing factors for adverse reproductive outcomes in patients with positive TPOAb and the establishment of a nomogram prediction model - Nature
Analysis of the influencing factors for adverse reproductive outcomes in patients with positive TPOAb and the establishment of a nomogram prediction model Nature
Published: June 4, 2025, 12:59 p.m.
Upregulation of miR-183 inhibits the invasion and migration of endometrial stromal cells in endometriosis patients by downregulating Ezrin - Frontiers
Upregulation of miR-183 inhibits the invasion and migration of endometrial stromal cells in endometriosis patients by downregulating Ezrin Frontiers
Published: June 3, 2025, 6:52 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - BioSpace
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial BioSpace
Published: June 2, 2025, 11:48 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - GlobeNewswire
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial GlobeNewswire
Published: June 2, 2025, 6:32 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Yahoo Finance
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Yahoo Finance
Published: June 2, 2025, 6:30 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Yahoo
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Yahoo
Published: June 2, 2025, 6:30 p.m.
Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer - Medical Xpress
Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer Medical Xpress
Published: June 2, 2025, 6:20 p.m.
Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer | Newswise - Newswise
Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer | Newswise Newswise
Published: June 2, 2025, 2:25 p.m.
When doctors don’t believe their patients’ pain – experts explain the all-too-common experience of medical gaslighting - Cobb Courier
When doctors don’t believe their patients’ pain – experts explain the all-too-common experience of medical gaslighting Cobb Courier
Published: June 2, 2025, 10:07 a.m.
Link copied to clipboard!